

ICMJE DISCLOSURE FORM

Date: 3/4/2025

Your Name: Ulrike Protzer

Manuscript Title: Chimeric Antigen Receptor (CAR) T-cell Therapy Engineering Immune Cells To Treat Liver Diseases

Manuscript Number (if known): JHEPAT-D-24-02926

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
Time frame: Since the initial planning of the work										
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div> <input type="checkbox"/> None </div> <table border="1"> <tr> <td>German Research foundation (DFG) via TRR338, project No. 452881907</td> <td>Research grant to institution (TUM)</td> </tr> <tr> <td>BayCellator consortium</td> <td>Research grant to institution (TUM)</td> </tr> <tr> <td>European Union's Horizon 2020 research and innovation programme: TherVacB Consortium;</td> <td>Research grant to institution (Helmholtz Munich)</td> </tr> <tr> <td>Support through the German Center for Infection Research (DZIF), project HBV Cure</td> <td>Research grant to institution (Helmholtz Munich)</td> </tr> </table>	German Research foundation (DFG) via TRR338, project No. 452881907	Research grant to institution (TUM)	BayCellator consortium	Research grant to institution (TUM)	European Union's Horizon 2020 research and innovation programme: TherVacB Consortium;	Research grant to institution (Helmholtz Munich)	Support through the German Center for Infection Research (DZIF), project HBV Cure	Research grant to institution (Helmholtz Munich)	
German Research foundation (DFG) via TRR338, project No. 452881907	Research grant to institution (TUM)									
BayCellator consortium	Research grant to institution (TUM)									
European Union's Horizon 2020 research and innovation programme: TherVacB Consortium;	Research grant to institution (Helmholtz Munich)									
Support through the German Center for Infection Research (DZIF), project HBV Cure	Research grant to institution (Helmholtz Munich)									
Time frame: past 36 months										
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div> <input type="checkbox"/> None </div> <table border="1"> <tr> <td>SCG Cell Therapy</td> <td>Research grant to institution</td> </tr> <tr> <td>CNAT-M (with Ethris and XL Protein)</td> <td>Research grant to institution</td> </tr> <tr> <td>Roche Diagnostics</td> <td>Collaborative research grant to institution</td> </tr> <tr> <td></td> <td></td> </tr> </table>	SCG Cell Therapy	Research grant to institution	CNAT-M (with Ethris and XL Protein)	Research grant to institution	Roche Diagnostics	Collaborative research grant to institution			
SCG Cell Therapy	Research grant to institution									
CNAT-M (with Ethris and XL Protein)	Research grant to institution									
Roche Diagnostics	Collaborative research grant to institution									
3	<div>Royalties or licenses</div> <div> <input checked="" type="checkbox"/> None </div> <table border="1"> <tr> <td>SCG Cell Therapy</td> <td>License of S-CAR, HBV-specific TCRs from Helmholtz Munich</td> </tr> <tr> <td>SCG Cell Therapy</td> <td>License of T-cell engager antibodies from Helmholtz Munich</td> </tr> <tr> <td></td> <td></td> </tr> </table>	SCG Cell Therapy	License of S-CAR, HBV-specific TCRs from Helmholtz Munich	SCG Cell Therapy	License of T-cell engager antibodies from Helmholtz Munich					
SCG Cell Therapy	License of S-CAR, HBV-specific TCRs from Helmholtz Munich									
SCG Cell Therapy	License of T-cell engager antibodies from Helmholtz Munich									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)																								
4	Consulting fees	<input type="checkbox"/> None <table border="1"> <tr> <td>Aligos</td> <td>Personal fees</td> </tr> <tr> <td>Gilead</td> <td>Personal fees</td> </tr> <tr> <td>GSK</td> <td>Personal fees</td> </tr> <tr> <td>Sanofi</td> <td>Personal fees</td> </tr> <tr> <td>Abbvie</td> <td>Personal fees</td> </tr> </table>		Aligos	Personal fees	Gilead	Personal fees	GSK	Personal fees	Sanofi	Personal fees	Abbvie	Personal fees														
Aligos	Personal fees																										
Gilead	Personal fees																										
GSK	Personal fees																										
Sanofi	Personal fees																										
Abbvie	Personal fees																										
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td>Abbott</td> <td>Personal fees, speaker bureau</td> </tr> <tr> <td>MSD</td> <td>Personal fees, speaker bureau</td> </tr> <tr> <td>Gilead</td> <td>Personal fees, speaker bureau</td> </tr> <tr> <td></td> <td>Personal fees, speaker bureau</td> </tr> <tr> <td></td> <td></td> </tr> </table>		Abbott	Personal fees, speaker bureau	MSD	Personal fees, speaker bureau	Gilead	Personal fees, speaker bureau		Personal fees, speaker bureau																
Abbott	Personal fees, speaker bureau																										
MSD	Personal fees, speaker bureau																										
Gilead	Personal fees, speaker bureau																										
	Personal fees, speaker bureau																										
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>																									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>																									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>																									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None <table border="1"> <tr> <td>AATech</td> <td>Advisory board, personal fees</td> </tr> <tr> <td>Aligos</td> <td>Advisory board, personal fees</td> </tr> <tr> <td>Arbutus</td> <td>Advisory board, personal fees</td> </tr> <tr> <td>BioNTech</td> <td>Advisory board, no fees</td> </tr> <tr> <td>Leukocare</td> <td>Advisory board, personal fees</td> </tr> <tr> <td>J&J</td> <td>Advisory board, personal fees</td> </tr> <tr> <td>Merck</td> <td>Advisory board, personal fees</td> </tr> <tr> <td>Gilead</td> <td>Advisory board, personal fees</td> </tr> <tr> <td>GSK</td> <td>Advisory board, personal fees</td> </tr> <tr> <td>Sanofi Pasteur</td> <td>Advisory board, personal fees</td> </tr> <tr> <td>Sobi</td> <td>Advisory board, personal fees</td> </tr> <tr> <td>Roche</td> <td>Advisory board, no fees</td> </tr> </table>		AATech	Advisory board, personal fees	Aligos	Advisory board, personal fees	Arbutus	Advisory board, personal fees	BioNTech	Advisory board, no fees	Leukocare	Advisory board, personal fees	J&J	Advisory board, personal fees	Merck	Advisory board, personal fees	Gilead	Advisory board, personal fees	GSK	Advisory board, personal fees	Sanofi Pasteur	Advisory board, personal fees	Sobi	Advisory board, personal fees	Roche	Advisory board, no fees
AATech	Advisory board, personal fees																										
Aligos	Advisory board, personal fees																										
Arbutus	Advisory board, personal fees																										
BioNTech	Advisory board, no fees																										
Leukocare	Advisory board, personal fees																										
J&J	Advisory board, personal fees																										
Merck	Advisory board, personal fees																										
Gilead	Advisory board, personal fees																										
GSK	Advisory board, personal fees																										
Sanofi Pasteur	Advisory board, personal fees																										
Sobi	Advisory board, personal fees																										
Roche	Advisory board, no fees																										

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None <table border="1"> <tr> <td>German Center for Infection Research</td> <td>Executive Board, Topic-Lead Hepatitis</td> </tr> <tr> <td>University Hospital Cologne</td> <td>Supervisory board</td> </tr> <tr> <td>University of Regensburg</td> <td>Advisory board</td> </tr> </table>		German Center for Infection Research	Executive Board, Topic-Lead Hepatitis	University Hospital Cologne	Supervisory board	University of Regensburg	Advisory board
German Center for Infection Research	Executive Board, Topic-Lead Hepatitis								
University Hospital Cologne	Supervisory board								
University of Regensburg	Advisory board								
11	Stock or stock options	<input type="checkbox"/> None <table border="1"> <tr> <td>SCG Cell Therapy Inc</td> <td>Shareholder, stock option, board member</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		SCG Cell Therapy Inc	Shareholder, stock option, board member				
SCG Cell Therapy Inc	Shareholder, stock option, board member								
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>							
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>									

ICMJE DISCLOSURE FORM

Date: 3/5/2025

Your Name: Scott L. Friedman

Manuscript Title: Chimeric Antigen Receptor (CAR) T-cell Therapy Engineering Immune Cells To Treat Liver Diseases

Manuscript Number (if known): JHEPAT-D-24-02926

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	<div> <div></div> <div></div> <div></div> </div> Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None	<div> <div>NIH 2R01DK128289</div> <div></div> <div></div> </div>
3	Royalties or licenses	<input checked="" type="checkbox"/> None	<div> <div></div> <div></div> <div></div> </div>

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input type="checkbox"/> None <table border="1"> <tr><td>SEE ATTACHED</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		SEE ATTACHED							
SEE ATTACHED											
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None <table border="1"> <tr><td>Seminar</td><td>U. of Pittsburgh Liver Center</td></tr> <tr><td>Seminar</td><td>U. Pennsylvania NIDDK GI Center</td></tr> <tr><td>Visiting Professor</td><td>Baylor College of Medicine</td></tr> </table>		Seminar	U. of Pittsburgh Liver Center	Seminar	U. Pennsylvania NIDDK GI Center	Visiting Professor	Baylor College of Medicine		
Seminar	U. of Pittsburgh Liver Center										
Seminar	U. Pennsylvania NIDDK GI Center										
Visiting Professor	Baylor College of Medicine										
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td>Falk Foundation Meeting on Liver Immunology</td><td>Munich</td></tr> <tr><td>Keynote Speaker, International Congress of Diabetes and Metabolism</td><td>Gyeongyeon – South Korea</td></tr> <tr><td></td><td></td></tr> </table>		Falk Foundation Meeting on Liver Immunology	Munich	Keynote Speaker, International Congress of Diabetes and Metabolism	Gyeongyeon – South Korea				
Falk Foundation Meeting on Liver Immunology	Munich										
Keynote Speaker, International Congress of Diabetes and Metabolism	Gyeongyeon – South Korea										
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input type="checkbox"/> None	
		SEE ATTACHED	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			

ICMJE DISCLOSURE FORM

Date: 3/5/2025

Your Name: Michael Hudecek

Manuscript Title: Chimeric Antigen Receptor (CAR) T-cell Therapy Engineering Immune Cells To Treat Liver Diseases

Manuscript Number (if known): JHEPAT-D-24-02926

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input type="checkbox"/> None <table border="1"> <tr> <td>Funding: SFB TRR338 LETSimmun (DFG, German Research Foundation)</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>	Funding: SFB TRR338 LETSimmun (DFG, German Research Foundation)					Click the tab key to add additional rows.
Funding: SFB TRR338 LETSimmun (DFG, German Research Foundation)								
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None <table border="1"> <tr> <td>BMS</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	BMS					
BMS								
3	Royalties or licenses	<input type="checkbox"/> None <table border="1"> <tr> <td>Fred Hutch Cancer Center, Seattle, WA</td> <td></td> </tr> <tr> <td>Julius Maximilians University, Würzburg, GER</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	Fred Hutch Cancer Center, Seattle, WA		Julius Maximilians University, Würzburg, GER			
Fred Hutch Cancer Center, Seattle, WA								
Julius Maximilians University, Würzburg, GER								

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None <table border="1"> <tr><td>Janssen, Kite/Gilead, BMS</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Janssen, Kite/Gilead, BMS							
Janssen, Kite/Gilead, BMS											
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input type="checkbox"/> None <table border="1"> <tr><td>Fred Hutch Cancer Center, Seattle, WA</td><td></td></tr> <tr><td>Julius Maximilians University, Würzburg, GER</td><td></td></tr> <tr><td></td><td></td></tr> </table>		Fred Hutch Cancer Center, Seattle, WA		Julius Maximilians University, Würzburg, GER					
Fred Hutch Cancer Center, Seattle, WA											
Julius Maximilians University, Würzburg, GER											
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None <table border="1"> <tr><td>Kite/Gilead</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Kite/Gilead							
Kite/Gilead											
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input type="checkbox"/> None	
		Co-founder and equity owner, T-CURX GmbH, Würzburg, Germany	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 8/26/2021

Your Name: Elmar Jaeckel

Manuscript Title: Chimeric Antigen Receptor (CAR) T-cell Therapy Engineering Immune Cells To Treat Liver Diseases

Manuscript Number (if known): JHEPAT-D-24-02926

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	<table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td>Click the tab key to add additional rows.</td></tr> </table>						Click the tab key to add additional rows.
	Click the tab key to add additional rows.								
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	<table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
3	Royalties or licenses	<input checked="" type="checkbox"/> None	<table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input type="checkbox"/> None <table border="1"> <tr> <td>Quell Therapeutics, London, UK</td> <td>Payments to me as founder of the company</td> </tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> </table>		Quell Therapeutics, London, UK	Payments to me as founder of the company						
Quell Therapeutics, London, UK	Payments to me as founder of the company										
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> </table>									
6	Payment for expert testimony	<input type="checkbox"/> None <table border="1"> <tr> <td>Quell Therapeutics, London, UK</td> <td> </td> </tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> </table>		Quell Therapeutics, London, UK							
Quell Therapeutics, London, UK											
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> </table>									
8	Patents planned, issued or pending	<input type="checkbox"/> None <table border="1"> <tr> <td>Quell Therapeutics, London, UK</td> <td> </td> </tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> </table>		Quell Therapeutics, London, UK							
Quell Therapeutics, London, UK											
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None <table border="1"> <tr> <td>Quell Therapeutics, London, UK</td> <td> </td> </tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> </table>		Quell Therapeutics, London, UK							
Quell Therapeutics, London, UK											
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> <tr><td> </td><td> </td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input type="checkbox"/> None	
		Quell Therapeutics, London, UK	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.